Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2024 March Clinical trials Venetoclax monotherapy leads to durable responses in R/R chronic lymphocytic leukaemia patient... Read more
2024 March Clinical trials Immunoglobulin gene rearrangement test for bone marrow involvement in cases of DLBCL Read more
2024 March Clinical trials Efficacy of tabelecleucel in R/R EBV-positive post-transplant lymphoproliferative disease Read more
2024 February Clinical trials MRD-guided ibrutinib and venetoclax regimen improves PFS in CLL patients Read more
2024 January Clinical trials Golidocitinib shows promising results in patients with refractory/relapsed peripheral T-cell l... Read more
2024 January Clinical trials Adding daratumumab to VRd results in improved PFS in multiple myeloma Read more
Top
